Human papillomavirus vaccines and vaccine implementation

Area of Science:

• Immunology
• Public Health
• Oncology

Background:

• Countries face challenges with rapid vaccine development for primary infection prevention.
• Several vaccines are candidates for routine immunization programs.
• Two new vaccines against human papillomavirus (HPV) types have been commercialized: bivalent (Cervarix) and quadrivalent (Gardasil).

Purpose of the Study:

• To summarize the global burden of HPV-preventable diseases.
• To describe the impact of secondary prevention strategies.
• To outline the aspects, efficacy, and safety of current HPV vaccines.

Main Methods:

• Review of worldwide HPV disease burden.
• Analysis of secondary prevention effectiveness.
• Evaluation of available HPV vaccine data.

Main Results:

• Bivalent and quadrivalent HPV vaccines are available and used in some countries.
• These vaccines prevent HPV infection, cervical cancer, other HPV-related cancers, and genital warts (quadrivalent).
• The primary beneficiaries of these vaccines are women.

Conclusions:

• The article provides an overview of HPV disease burden and prevention strategies.
• It discusses the efficacy and safety of current HPV vaccines.
• Key factors influencing global vaccine introduction, particularly in developing countries, are highlighted.